Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Prostate cancer epidemiology.

Grönberg H.

Lancet. 2003 Mar 8;361(9360):859-64. Review.

PMID:
12642065
2.

Update on chemoprevention of prostate cancer.

Klein EA, Thompson IM.

Curr Opin Urol. 2004 May;14(3):143-9. Review.

PMID:
15069304
3.

Prostate cancer: a serious disease suitable for prevention.

Fitzpatrick JM, Schulman C, Zlotta AR, Schröder FH.

BJU Int. 2009 Apr;103(7):864-70. doi: 10.1111/j.1464-410X.2008.08206.x. Review.

4.

Prostate cancer prevention trials in the USA.

Brawley OW, Parnes H.

Eur J Cancer. 2000 Jun;36(10):1312-5. Review.

PMID:
10882873
5.

The future of prostate cancer prevention.

Brawley OW, Barnes S, Parnes H.

Ann N Y Acad Sci. 2001 Dec;952:145-52. Review.

PMID:
11795434
6.

SELECT: the selenium and vitamin E cancer prevention trial.

Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C.

Urol Oncol. 2003 Jan-Feb;21(1):59-65. Review.

PMID:
12684129
7.

Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.

Goetzl MA, Holzbeierlein JM.

Nat Clin Pract Urol. 2006 Aug;3(8):422-9. Review.

PMID:
16902518
8.

Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.

Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM.

J Clin Oncol. 2005 Mar 20;23(9):1911-20. Review.

PMID:
15774783
9.

[Prostate cancer. Introduction].

Kakizoe T.

Nihon Rinsho. 2005 Feb;63(2):199-200. Review. Japanese.

PMID:
15714965
10.

Prevention of prostate cancer.

DePrimo SE, Shinghal R, Vidanes G, Brooks JD.

Hematol Oncol Clin North Am. 2001 Jun;15(3):445-57. Review.

PMID:
11525290
11.

Five-alpha-reductase Inhibitors for prostate cancer prevention.

Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091. doi: 10.1002/14651858.CD007091. Review.

PMID:
18425978
12.

The clinical implications of the prostate cancer prevention trial.

Marberger M, Adolfsson J, Borkowski A, Fitzpatrick J, Kirk D, Prezioso D, Rabaça C, Solsona E, Teillac P.

BJU Int. 2003 Nov;92(7):667-71. Review. No abstract available.

13.

Pharmacological approaches to reducing the risk of prostate cancer.

Rittmaster RS, Fleshner NE, Thompson IM.

Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. Review.

PMID:
19200641
14.

Chemoprevention of prostate cancer with finasteride.

Thompson I, Feigl P, Coltman C.

Important Adv Oncol. 1995:57-76. Review. No abstract available.

PMID:
7672814
15.

High-grade prostate cancer and finasteride.

Lebdai S, Bigot P, Azzouzi AR.

BJU Int. 2010 Feb;105(4):456-9. doi: 10.1111/j.1464-410X.2009.09089.x. Epub 2009 Nov 20. Review.

16.

Can prostate cancer be prevented?

Klein EA.

Nat Clin Pract Urol. 2005 Jan;2(1):24-31. Review.

PMID:
16474573
17.

Update on prostate cancer chemoprevention.

Lowe JF, Frazee LA.

Pharmacotherapy. 2006 Mar;26(3):353-9. Review.

PMID:
16503715
18.

Hormonal prevention of prostate cancer.

Brawley OW.

Urol Oncol. 2003 Jan-Feb;21(1):67-72. Review.

PMID:
12684130
19.

[Prostate cancer chemoprevention].

Krysiak R, Okopień B, Szkróbka W, Herman ZS.

Przegl Lek. 2005;62(9):929-33. Review. Polish.

PMID:
16541732
20.

The finasteride prostate cancer prevention trial (PCPT)--what have we learned?

Mellon JK.

Eur J Cancer. 2005 Sep;41(13):2016-22. Review.

PMID:
16061372
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk